Abstract | AIMS/HYPOTHESIS: METHODS: RESULTS:
GLP-1 analogue therapy reduced levels of the inflammatory macrophage activation molecule sCD163 (220 ng/ml vs 171 ng/ml, p < 0.001). This occurred independent of changes in body weight, fructosamine and HbA1c. GLP-1 analogue therapy was associated with a decrease in levels of the inflammatory cytokines TNF-α (264 vs 149 pg/ml, p < 0.05), IL-1β (2,919 vs 748 pg/ml, p < 0.05) and IL-6 (1,379 vs 461 pg/ml p < 0.05) and an increase in levels of the anti-inflammatory adipokine adiponectin (4,480 vs 6,290 pg/ml, p < 0.002). CONCLUSIONS/INTERPRETATION:
|
Authors | Andrew E Hogan, Gadintshware Gaoatswe, Lydia Lynch, Michelle A Corrigan, Conor Woods, Jean O'Connell, Donal O'Shea |
Journal | Diabetologia
(Diabetologia)
Vol. 57
Issue 4
Pg. 781-4
(Apr 2014)
ISSN: 1432-0428 [Electronic] Germany |
PMID | 24362727
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Inflammation Mediators
- Glucagon-Like Peptide 1
|
Topics |
- Body Weight
(drug effects)
- Diabetes Mellitus, Type 2
(drug therapy, immunology)
- Female
- Glucagon-Like Peptide 1
(analogs & derivatives, therapeutic use)
- Humans
- Immunity, Innate
(drug effects)
- Inflammation
(drug therapy)
- Inflammation Mediators
(therapeutic use)
- Male
- Middle Aged
|